医疗科技领域的人工智能：驾驭变革与机遇

Artificial Intelligencein Medtech:Navigating Foreword from Elizabeth Orr, Managing Editor,Policy and Regulation, Medtech Insight: Artificial intelligence isn’t just reshapingthe future – it’s sculpting the present. Fromclassrooms to concert halls, AI is changing howwe learn, work, and create. And the medtechindustry is no exception. The US FDA has •Where the next wave is headed:A preview ofthe patient-focused deals analysts expect tosee in the coming months and years.•The human factor:Johnson & JohnsonMedtech research revealing what clinicians •Regulation and reality:How California’stough patient privacy laws are shaping The pace is dizzying, and missing a beat couldmean falling behind for good. This collection ofin-depth, forward-looking articles from Medtech You’ll also get exclusive previews of twosubscriber-only deep dives – one analyzingstakeholder feedback on the FDA’s latest AIguidance, and another exploring how to help •AI dealmaking:$9.2bn in medtech AI mergersand acquisitions were announced in the first Subscribe todayfor full access to these features and ongoing coverageof AI, digital health, and other technologies reshaping medtech. Industry Experts Expect AI-DrivenMedtech M&A To Continue In 2025 Marion Webb AI-driven medtech M&A slowed slightly in volume but tripledin value in early 2025, with buyers focusing on AI-drivendiagnostics, surgical tech and analytics. Industry expertsexpect continued high-value deals as firms defend market Executive Summary When it comes to M&A activity in medtech,buyers’ appetite has been on AI-powereddiagnostics,surgical solutions and dataanalytics, a trend that industry insiders expect Key Takeaways •Q1 2025 medtech M&A fell from 62 to57deals, but deal value jumped from$2.7bnto $9.2bn, reflecting focus on Although the number of M&A deals dippedslightly in the first quarter from 62 to 57,the combined value surged from $2.7bn to$9.2bn. This shift reflects a stronger emphasison mature companies with deeper product •AI-powered surgical, diagnostic anddata-driven platforms remain top Industry Experts Expect AI-DrivenMedtech M&A To Continue In 2025 and procedure optimization to postoperativeoutcome. Surgical Technologies One of the largest transactions was Stryker’s$4.9bn acquisition of Inari Medical, expandingStryker’s portfolio in the cardiovascularand peripheral markets. Inari’s proprietarythrombectomy devices generate real-time He also anticipates that those medtechs with aparticular portfolio of devices will be looking toacquire AI-enabled technologies to help provide “Typically, those companies don’t have theresources internally” to create and implement Since the deal was announced, Inari haslaunched its second-generation InThrillThrombectomy System for clot removal and Not all activity will be growth-driven. Deepak Sahu, managing director at consultingfirm Trinity Life Sciences, predicts that manydeals for the remainder of the year will bedefensive as medtechs brace for financialpressures on health systems. Factors such as Other notable deals in the surgical spaceinclude Boston Scientific’s $900m acquisitionof Bolt Medical and, with it, its intravascularlithotripsy laser-based platform for treatingcoronary and peripheral artery disease. In “So, when that happens, you are seeing thestock of medical devices either remainingflat, single low-digit growth or companies willsee their share price crashing,” Sahu said. Inresponse, he expects that medtechs will look The sector also saw large scale transactionsoutside of surgery. Among the recent notable M&A deals areWaters Corp.’s $17.5bn buyout of BectonDickinson’s LifeSciences business, Alcon’s$1.5bn purchase of STAAR Surgical, HistoSonics’$2.25bn management-led majority stakeacquisition by a syndicate of private and public Challenges Despite billions of dollars flowing into AI,adoption hurdles remain. Most FDA-cleared AI-enabled medical devicesare concentrated in radiology and pathology toenhance image quality, speed up workflow or Defensive Buying Strategies For 2025, Bryan Hughes, managing directorat investment banking firm P&M CorporateFinance,expects M&A activity to stay focused “That’s why GE and Philips and other companieslike that have been leaders in that space,” Industry Experts Expect AI-DrivenMedtech M&A To Continue In 2025 In Europe, regulatory distraction from theMedical Device Regulation (MDR) rollout hasbegun to ease, which will allow medtechsto focus on innovation again, he said. Still, Hughes said, noting that from a regulatoryperspective, there is now more convergence on“how far the [US Food and Drug Administration] Also, “The FDA, as much as it is saying theirreviewers are now using AI to do all their reviewsand everything else, it is slow moving, very slowmoving,” Hughes said. He also pointed out that With medtech companies expected to investupward of $10bn annually into AI by 2025,the industry appears to be set for fewer buthigher-value deals as firms double